08:05 – 08:05: Welcome
08:05 – 08:20: Clinical Trial Shaping Our Next Step – Partnership between Investigators and Patients - Karen Kelly
08:20 – 08:30: Electronic Cigarettes and Vaping - Anthony Alberg
08:30 – 08:45: Imaging to Identify and Characterize Lung Nodules - Herbert MacMahon
08:45 – 08:55: Molecular Biomarkers in Early Detection of Lung Cancer - Peter Mazzone
08:55 – 09:05: How Lung Cancer Advocacy and Research Has Changed in the Past Years - Jill Feldman
09:05 – 09:15: The Increasing Importance of Social Media in Advocacy - Brendon Stiles
09:15 – 09:25: Financial Toxicity of Cancer Therapy - Fumiko Chino
09:25 – 09:45: Panel Discussion with all Speakers

10:15 – 10:20: Introduction - Charu Aggarwal
10:20 – 10:30: Innovations in Broad Sequencing Including Fusion Detection and Cellularity Constraints - Marc Ladanyi
10:30 – 10:40: TMB Ready for Prime Time? - John Longshore
10:40 – 10:50: Incorporating Blood Biomarkers into Clinical Practice - Charu Aggarwal
10:50 – 11:00: Genomic Biomarkers of Immunotherapy Sensitivity and Resistance - Ferdinandos Skoulidis
11:00 – 11:15: Panel Discussion

10:15 - 10:20: Introduction - Jessica Donington
10:20 – 10:28: Pre-habilitation/Patient Selection and Enhanced Recovery after Surgery (ERAS) - Katherine Kuhns
10:28 – 10:36: Induction Strategies for Stage II/IIIA NSCLC Including Radiation and IO - Jessica Donington
10:36 – 10:44: Role of IO and SBRT for Inoperable Early Stage NSCLC - Cliff Robinson
10:44 – 10:52: Recurrence after SBRT - Mara Antonoff
10:52 – 11:00: Assessment and Management of IO Toxicity in Combined Modality Trials - Mary Jo Fidler
11:00 – 11:15: Panel Discussion

12:45 – 12:50: Introduction - Evertt Vokes
12:50 – 13:35: NCI Perspective - Douglas R. Lowy, NCI Acting Director
13:35 – 13:45: Q&A

08:15 – 08:18: Introduction - Lecia Sequist
08:18 – 08:25: Treatment of New and Emerging Driver Mutations - Paul Paik
08:25 – 08:32: Updates in ALK - Caroline McCoach
08:32 – 08:39: Progression after First Line Osimertinib - Lecia Sequist
08:39 – 08:46: Clinical Trials in MPM - Hedy Lee Kindler
08:46 – 08:52: SCLC – Updates - Anna Farago
08:52 – 09:00: CNS Disease- Systemic Therapy as First Line – From a Radiation Oncology Perspective - Vinai Gondi
09:00 – 09:15: Panel Discussion

08:15 – 08:20: Introduction
08:20 – 08:28: Rebiopsy after Progressive Disease, Pseudoprogression, Adjudication of Site Selection - George Eapen
08:28 – 08:35: Management of Malignant Effusion (TKIs and IO) - Carla Lamb
08:35 – 08:43: MPR Post Neo-adjuvant IO - Ignacio Wistuba
08:43 – 08:51: Diagnostic and Management Dilemmas in Synchronous NSCLC - Elizabeth David
08:51 – 08:59: Ablative Radiation Therapy for Operable Disease - Megan Daly
08:59 – 09:15: Panel Discussion

11:30 – 11:45: Novel Tumor Biomarkers and Tumor Immune Profiling - Kurt Schalper
11:45 – 12:00: Microbiome and Implications for Response to IO - Thomas Gajewski
12:00 – 12:15: Treatment of Oligometastaic Disease Denovo and at Progression with Driver Mutations, on IO or Neither - Puneeth Iyengar and Luda Bazhenova
12:15 – 12:30: Closing Remarks